megestrol acetate

(redirected from Megace ES)
Also found in: Dictionary, Thesaurus.
Related to Megace ES: megestrol acetate

megestrol acetate

Apo-Megestrol (CA), Megace, Megace ES, Megace-OS (CA), Nu-Megestrol

Pharmacologic class: Hormone

Therapeutic class: Progestin, antineoplastic, appetite stimulant

Pregnancy risk category D (tablets), X (suspension)

Pregnancy risk category D (tablets), X (suspension)


Unknown. Thought to suppress growth of progestin-sensitive breast and endometrial tumors by inhibiting pituitary and adrenal function.


Oral suspension: 40 mg/ml

Oral suspension (concentrate): 625 mg/5 ml

Tablets: 20 mg, 40 mg

Indications and dosages

Breast cancer

Adults: 160 mg/day P.O. given as 40 mg P.O. q.i.d.

Endometrial cancer

Adults: 40 to 320 mg/day P.O. in divided doses

Anorexia, cachexia, or unexplained significant weight loss in AIDS patients

Adults: 800 mg (oral suspension only) P.O. daily, or 625 mg (oral suspension concentrate) P.O. daily

Off-label uses

• Endometriosis, endometrial hyperplasia
• Prostatic hypertrophy
• Contraception


• Hypersensitivity to drug or its components
• Known or suspected pregnancy (suspension only)


Use cautiously in:
• diabetes mellitus, severe hepatic disease, renal disease, cardiovascular disease, seizure disorders, cerebral hemorrhage, migraine, asthma, undiagnosed vaginal bleeding, depression
• history of thrombophlebitis
• breastfeeding.


• Give with meals if GI upset occurs.

Adverse reactions

CNS: headache, insomnia, drowsiness, asthenia, confusion, neuropathy, hyperesthesia, abnormal thinking, paresthesias, depression, seizures

CV: hypertension, chest pain, thrombophlebitis, deep vein thrombosis

EENT: amblyopia, retinal thrombosis, pharyngitis

GI: nausea, vomiting, constipation, abdominal pain, flatulence, dyspepsia, dry mouth, increased salivation, oral candidiasis

GU: breast tenderness, breakthrough bleeding, decreased libido

Hematologic: anemia, leukopenia

Hepatic: hepatomegaly

Metabolic: hyperglycemia

Musculoskeletal: carpal tunnel syndrome, back pain

Respiratory: dyspnea, cough, pneumonia, pulmonary embolism

Skin: alopecia, rash, pruritus, sweating

Other: edema, fever, weight gain, herpes infection


Drug-diagnostic tests.Lactate dehydrogenase: increased level

Patient monitoring

Watch for signs and symptoms of thromboembolic disorders.

Stay alert for visual disturbances, headache, abdominal pain, and hepatomegaly.
• Monitor glucose level in diabetic patients.

Patient teaching

• Inform patient that drug may cause back or abdominal pain, headache, nausea, vomiting, or breast tenderness.

Tell patient to immediately report pain, swelling or redness of lower legs, chest or back pain, or shortness of breath.
• Advise patient to contact prescriber if adverse effects become pronounced or if other troublesome signs or symptoms occur.
• Urge patient to use reliable contraception.

Instruct patient to immediately report suspected pregnancy.
• Caution female patient to avoid breastfeeding.
• Advise diabetic patient to monitor blood glucose level.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

megestrol acetate

an antineoplastic progestational agent.
indications It is prescribed to treat endometrial cancer and more commonly to palliate advanced endometrial and breast cancer. It is also used to stimulate appetite and to promote weight gain in cachexia patients.
contraindication Hypersensitivity to the drug prohibits its use.
adverse effects Adverse effects include edema and breakthrough bleeding.

megestrol acetate

A synthetic progestin/progestational anti-androgen that blocks oestrogenic effects, androgen production and androgen-mediated activity, reducing serum gonadotropin and testosterone. It reduces hot flushes by 85% in menopausal women and androgen-deprived men compared to 20% in placebo group.

Megestrol acetate is used to manage weight loss and anorexia in patients with AIDs and breast, endometrial and prostate cancer. In combination with oestradiol, it maintains castrate levels of testosterone in patients with metastatic prostate cancer.

Adverse effects
Dysmenorrhoea, chest pain, depression, oedema in hands and feet, brown spots on skin, hirsutism, breast tenderness, hypertension, venous thrombosis.

megestrol acetate

Megace® Endocrinology A synthetic progestin/
progestational antiandrogen that blocks estrogenic effects, androgen production and androgen-mediated activity, ↓ serum gonadotropin and testosterone  Oncology A progestin used to manage weight loss, anorexia in Pts with AIDs, breast, endometrial, and rarely prostate CA Adverse effects Dysmenorrhea, chest pain, depression, edema in hands, feet, brown spots on skin, hirsutism, breast tenderness, HTN, venous thrombosis

megestrol acetate

(məjes´trōl as´ətāt),
n brand name: Megace;
drug class: antineoplastic (progestin);
action: affects endometrium by antiluteinizing effect;
uses: breast, endometrial cancer, renal cell cancer.

megestrol acetate

a synthetic progestational agent, commonly used for estrus control in dogs and cats and also in the treatment of behavioral abnormalities and a variety of inflammatory skin diseases, including miliary dermatitis and eosinophilic granuloma.
References in periodicals archive ?
You should not take Megace ES if you are hypersensitive to megestrol acetate or any component of the formulation.
Be sure to tell your healthcare provider if you experience any side effects while taking Megace ES.
TWi's Abbreviated New Drug Application ("ANDA") for its generic version of MEGACE ES was approved by US FDA on August 27, 2014.
According to IMS Health, a market research firm, the total annual sales of Megace ES in the U.
Just weeks into her employment, during her training, she discovered Par's plan to promote Megace ES to an exclusively off-label patient population - elderly residents of long-term facilities.
Megace ES was the first branded pharmaceutical product developed by Par to be approved for marketing by the FDA.
4% of total Strativa revenue, decreased compared to the first quarter of 2008 due to lower sales of Megace ES and increased rebates.
For those AIDS patients with a lack of appetite who may have difficulty eating without the help of medication, Megace ES meets a critical need.
In its first year of marketing, the appetite stimulant Megace ES (megestrol acetate) 625 mg/5 mL concentrated oral suspension achieved sales of $15.
Megace ES 625 mg/5 mL and megestrol acetate oral suspension 800 mg/20 mL are contraindicated in patients with a history of hypersensitivity to megestrol acetate or any component of the formulation, or patients with known or suspected pregnancy.
Megace ES and megestrol acetate oral suspension are indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS).
The third quarter benefited from the introduction of Megace ES and an improving gross margin," said Scott Tarriff, president and chief executive officer.